CoChat

Decitibine improve the efficiency of anti-PD-1 therapy via activating the response to IFN/PD-L1 signal of lung cancer cells

The DOI matches its Crossref record; 24 of the 24 references it cites were found in a registry or an index.

Abstract

IFN-γ-induced PD-L1 expression represents the existence of tumor-specific T cells, which predicts high-response rate to anti-PD-1/L1 therapy, but loss-of-function of IFN signals (e.g., JAK mutation) induces adaptive immune resistance in patients with low-response rate. Interferon regulatory factors (IRF) are frequently epigenetic silenced in carcinogenesis, while the role of methylation in anti-PD-1/L1 therapy remains unclear. We here investigated the methylation status of IFN-γ related genes IRF1/8 and IFN-α/β-related genes IRF3/7 in lung cancer tissues and found that only highly methylated IRF1 and 7 negatively correlated to cd274 (coding PD-L1) expression, similar to JAK mutation. Interestingly, decitibine (DAC) as methylation inhibitor could hypomethylate IRF1/7 to restore PD-L1 level. Meanwhile, IRF7 enhanced constitutive PD-L1 expression, which was independent of IFN-γ though directly promote transcription of PD-L1, leading to abrogating cytotoxic T lymphocytes (CTLs) generation which could be restored by anti-PD-L1 antibody, or siRNA-IRF7. The supplement of DAC to anti-PD-1 therapy in vivo improve the efficiency of anti-tumor with less methylated IRF1/7, more interferon-related genes expression (e.g., CXCL9) and IFN-γ/CD8+ T-cells infiltrations, suggesting that additional treatment of DAC could rescue the ability to response to IFN in lung cancer patients with anti-PD-1/L1 therapy resistance.

Overview

Integrity signals

Registry

Crossref · 10.1038/s41388-018-0125-3

Cites

24 of 24 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Citations

Cites

Show all 24 references

Cited by

See all 81

Metadata

Authors
Lai, Q., Wang, H., Li, A., Xu, Y., Tang, L., Chen, Q., Zhang, C., Gao, Y., Song, J., & Du, Z.
Affiliations
  • Central South University (CN)
  • Guilin Medical University (CN)
Corresponding author
  • Song, Jianfei
  • Du, Zhenzong
Venue
Oncogene
Published
2018-02-09
Volume
37
Issue
17
Pages
2302-2312
ISSN
  • 0950-9232 (ISSN-L)
  • 1476-5594
OpenAlex
W2793835936
Cited by
69
References
24
Citations by year
2026: 2 · 2025: 4 · 2024: 7 · 2023: 13 · 2022: 8 · 2021: 13 · 2020: 7 · 2019: 8 · 2018: 7
FWCI
3.31
Type
journal article
Language
en
Open access
closed
Licence
www.springer.com/tdm (tdm)
Locations
  • Oncogene (publishedVersion)
  • PubMed (publishedVersion)
Topics
  • Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
  • Life Sciences › Immunology and Microbiology › Immunology › interferon and immune responses
  • Life Sciences › Immunology and Microbiology › Immunology › Immunotherapy and Immune Responses
Keywords
anti-PD-1 therapy, PD-L1 expression, lung cancer, DNA methylation, IRF1, IRF7, interferon signaling, JAK mutations, immune checkpoint inhibitor resistance, cytotoxic T lymphocytes, CD8+ T cells, CXCL9, epigenetic therapy
MeSH terms
A549 Cells, Decitabine, Adult, Aged, Aged, 80 and over, Animals, Antibodies, Monoclonal, Antineoplastic Combined Chemotherapy Protocols, Drug Synergism, Female, Humans, Interferons, Lung Neoplasms, Male, Mice, Inbred C57BL, Middle Aged, Signal Transduction, Carcinoma, Lewis Lung, Xenograft Model Antitumor Assays, Cell Line, Tumor, Mice, HEK293 Cells, Programmed Cell Death 1 Receptor

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Decitibine improve the efficiency of anti-PD-1 therapy via activating the response to IFN/PD-L1 signal of lung cancer cells. https://app.cochat.ai/papers/10.1038/s41388-018-0125-3
The paper
Lai, Q., Wang, H., Li, A., Xu, Y., Tang, L., Chen, Q., Zhang, C., Gao, Y., Song, J., & Du, Z. (2018). Decitibine improve the efficiency of anti-PD-1 therapy via activating the response to IFN/PD-L1 signal of lung cancer cells. Oncogene. https://doi.org/10.1038/s41388-018-0125-3

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.